Johnson & Johnson’s (JNJ) $16.6 billion deal to buy heart pump maker Abiomed (ABMD) will boost its pharmaceutical and medical device businesses before J&J plans to spin off its consumer division into a separate company. The acquisition of Abiomed is expected to be completed by the end of the first quarter of 2023. The spin-off …
Continue reading “J&J’s almost $17 billion bid for Abiomed reveals precisely why we personal it”

